A total of $3.2 million fund is awarded to Drs. Leuthardt and Chen for five years in support of their clinical study of an ultrasound-mediated blood-based liquid biopsy technique for noninvasive molecular diagnosis of glioblastoma. Glioblastoma patients will be recruited to evaluate the feasibility and safety of this technique. Developing a noninvasive technique to diagnose and monitor brain tumors will fundamentally advance personalized care for patients with malignant brain tumors. In addition to the standard diagnostics of anatomic imaging and surgical histology, the proposed technique has the potential to become the third pillar for brain tumor management by radically advancing the ability to easily and regularly acquire tumor genetic and molecular signatures.
Chen Ultrasound Lab receives R01 from NCI in collaboration with Dr. Eric Leuthardt
